These findings demonstrated that TPX2 lactylation is a critical mechanism for cell cycle regulation contributing to HCC progression, suggesting that inhibition of the lactate/TPX2 lactylation/AURKA axis might be a promising therapeutic cancer strategy. Here, AURKA is linked to hepatocellular carcinoma.